Our ambition is to change lives by changing the course of blood cancer.

Learn more

Latest Updates

Research & Development

Geron announces FDA acceptance of New Drug Application for imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS)

Learn more

Research & Development

Geron announces FDA Oncologic Drugs Advisory Committee (ODAC) votes in favor of clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk MDS

Research & Development

Geron announces fifty percent enrollment in the Phase 3 IMpactMF clinical trial for relapsed/refractory myelofibrosis (MF)

Events

View all

Investor Event

Geron to participate at investor conferences in April

John Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, to present at the 23rd Annual Needham Virtual Healthcare Conference on April 10 and Stifel’s 2024 Virtual Targeted Oncology Days on April 17.

For more information:

View the press release

Medical Congress

Geron data presentations at NCCN and HOPA 2024 Annual Conferences

Geron presented data at the National Comprehensive Cancer Network (NCCN) Annual Conference and the Hematology/Oncology Pharmacy Association Annual Conference (HOPA).

View the presentations here: